Difference between revisions of "Part:BBa K3711052"
| Line 19: | Line 19: | ||
This is a composite part for extracellular expression of FMO dimer. FMO dimer is expressed and participates in the production from indole to indigo. FMO dimer is reported to be more efficient than FMO. Pynr071c is the promoter of Aldose 1-isomerase superfamily protein YNR071C. In the presence of xylose, the signal peptide, α-factor , is used to express FMO dimer outside of the cell. | This is a composite part for extracellular expression of FMO dimer. FMO dimer is expressed and participates in the production from indole to indigo. FMO dimer is reported to be more efficient than FMO. Pynr071c is the promoter of Aldose 1-isomerase superfamily protein YNR071C. In the presence of xylose, the signal peptide, α-factor , is used to express FMO dimer outside of the cell. | ||
<h1>'''Usage and Biology'''</h1> | <h1>'''Usage and Biology'''</h1> | ||
| − | FMOs exist in the cell as a complex with a reduced form of the prosthetic group and NADPH cofactor, readying them to act on substrates. The 4-hydroperoxyflavin form of the prosthetic group represents a transient intermediate of the monooxygenation process. The oxygenated and reduced forms of the prosthetic group help stabilize interactions with cofactor and substrate alternately to permit continuous enzyme turnover. | + | FMOs exist in the cell as a complex with a reduced form of the prosthetic group and NADPH cofactor, readying them to act on substrates. The 4-hydroperoxyflavin form of the prosthetic group represents a transient intermediate of the monooxygenation process. The oxygenated and reduced forms of the prosthetic group help stabilize interactions with cofactor and substrate alternately to permit continuous enzyme turnover.[br] |
Whereas the enzyme–FAD and enzyme–FAD–NADPH complex structures have one dimer per unit cell of the P1 symmetry, the enzyme–FAD–methimazole complex has two. No conformational changes were evident when the three structures were compared in detail, permitting refinement with no crystallographic symmetry restraints. | Whereas the enzyme–FAD and enzyme–FAD–NADPH complex structures have one dimer per unit cell of the P1 symmetry, the enzyme–FAD–methimazole complex has two. No conformational changes were evident when the three structures were compared in detail, permitting refinement with no crystallographic symmetry restraints. | ||
***tu*** | ***tu*** | ||
Revision as of 08:39, 21 October 2021
Pynr071c-α factor-FMO dimer-AOX1 Terminator
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal XhoI site found at 1438
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 1495
Illegal NgoMIV site found at 2869
Illegal AgeI site found at 2714
Illegal AgeI site found at 4088 - 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 2717
Illegal BsaI site found at 4091
Description
This is a composite part for extracellular expression of FMO dimer. FMO dimer is expressed and participates in the production from indole to indigo. FMO dimer is reported to be more efficient than FMO. Pynr071c is the promoter of Aldose 1-isomerase superfamily protein YNR071C. In the presence of xylose, the signal peptide, α-factor , is used to express FMO dimer outside of the cell.
Usage and Biology
FMOs exist in the cell as a complex with a reduced form of the prosthetic group and NADPH cofactor, readying them to act on substrates. The 4-hydroperoxyflavin form of the prosthetic group represents a transient intermediate of the monooxygenation process. The oxygenated and reduced forms of the prosthetic group help stabilize interactions with cofactor and substrate alternately to permit continuous enzyme turnover.[br] Whereas the enzyme–FAD and enzyme–FAD–NADPH complex structures have one dimer per unit cell of the P1 symmetry, the enzyme–FAD–methimazole complex has two. No conformational changes were evident when the three structures were compared in detail, permitting refinement with no crystallographic symmetry restraints.
- tu***
After electrotransformed the FMO dimer into yeast, we still used Colony PCR to confirm the target gene is successfully transformed into the yeast cells.
- tu***
SDS-PAGE
At first, we tried to detect the protein in the supernatant, but no results were obtained. Because we have already experienced similar problems. We extracted the total protein directly and go for a purification to tested whether it was in the cell. Actually we detected the protein this time but it was smaller than expected.
- tu***
This indicated that the FMO dimer was broken in the process of expression or extraction. In order to confirm whether the catalytic effect is better, we also added indole to its medium to observe its effect on indigo synthesis.